[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100321916":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":71,"collaborators":74,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":25,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":25,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"The University of Texas at Arlington","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pioglitazone","ACTIVE_COMPARATOR","The subjects will be given 1 month supply of Pioglitazone pills. Pioglitazone is a class of anti-diabetic drugs called thiazolidinediones that are primarily used in the treatment of type 2 diabetes. The aim of the study is to determine if Pioglitazone also reduces ADMA and sympathetic nerve activity in CKD patients. This drug will be taken orally as a pill or capsule for one month. The dosage is 15 mg\u002Fday. This is on the lower dosage side for pioglitazone with the maximum dosage being 45mg\u002Fday. The research subjects are not responsible for the cost of the drug or for drug administration costs. The subjects will be verbally instructed to take 1 pill everyday by mouth, for 1 month. In addition, the pill bottle will be labeled with the same instructions.",[13],"Drug: Pioglitazone",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo pills are made of avicel microcrystalline cellulose and magnesium stearate, which are inactive ingredients in the Pioglitazone pills. The placebo pills will be of similar color and appearance as the Pioglitazone pills",[19],"Other: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Pioglitazone 15mg daily for 1 month",[9],null,{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo pills for 1 month",[15],[30],{"name":31,"affiliation":32,"role":33},"Paul J Fadel, PhD","University of Texas at Arlington","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","8172724653","Paul.Fadel@uta.edu",[40,57],{"facility":32,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Arlington","Texas","76010","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-97.10807,32.73569,{"lat":51,"lon":50},[54],{"name":31,"role":36,"phone":55,"phoneExt":25,"email":56},"817-272-4653","paul.fadel@uta.edu",{"facility":58,"status":41,"city":59,"state":43,"zip":60,"country":45,"countryCode":46,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"UT Southwestern","Dallas","75390",{"type":48,"coordinates":62},[63,64],-96.80667,32.78306,{"lat":64,"lon":63},[67],{"name":68,"role":36,"phone":69,"phoneExt":25,"email":70},"Robert Toto, MD","214-648-2744","Robert.Toto@UTSouthwestern.edu",{"type":33,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Paul Fadel","Professor",[75],{"name":76,"class":6},"University of Texas, Southwestern Medical Center at Dallas","100321916","phase-4-pioglitazone-to-reduce-sympathetic-overactivity-in-ckd-patients-100321916",false,"NCT03471117","Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients","Targeting ADMA With Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients","Inclusion Criteria:\n\n* CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL\u002Fmin\u002F1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.\n* Men and women 35 to 70 years of age\n\nExclusion Criteria:\n\n* Allergy to Glitazones\n* Myocardial infarction\n* Heart failure\n* Angina\n* History of kidney stones\n* Liver disease (abnormal liver enzymes)\n* Anemia (hemoglobin \\\u003C8 g\u002Fdl)\n* Cancer with current treatment\n* Previous organ transplantation\n* Immunosuppressant therapy\n* Human immunodeficiency virus infection\n* Pregnancy or lactating\n* Current tobacco use\n* Dilantin and oral contraceptive usage due to potential drug interaction with glitazones\n* Self-identified history of hypoglycemia","ALL","35 Years","70 Years",{"count":88,"type":89},28,"ESTIMATED","INTERVENTIONAL",[92],"PHASE4","Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function.\n\nThe goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.",[95],"Chronic Kidney Diseases",[97,98,99],"blood pressure","pioglitazone","hypertension","2025-06-07",{"date":102,"type":103},"2025-06-10","ACTUAL",{"date":105,"type":103},"2018-04-01",{"date":107,"type":89},"2026-04-01",{"name":5,"class":6},2]